LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of ...
Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...
Add Yahoo as a preferred source to see more of our stories on Google. Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy met the main goal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results